Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

1.

How effective are disease-modifying drugs in delaying progression in relapsing-onset ms?

Brenner SR, Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, Sketris IS.

Neurology. 2008 Aug 19;71(8):615; author reply 615-6. doi: 10.1212/01.wnl.0000324708.37575.5c. No abstract available.

PMID:
18711118
[PubMed - indexed for MEDLINE]
2.

How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?

Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, Sketris IS.

Neurology. 2007 Oct 9;69(15):1498-507. Epub 2007 Aug 15.

PMID:
17699802
[PubMed - indexed for MEDLINE]
3.

Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis.

Putzki N, Kollia K, Woods S, Igwe E, Diener HC, Limmroth V.

Eur J Neurol. 2009 Mar;16(3):424-6. doi: 10.1111/j.1468-1331.2008.02519.x.

PMID:
19187261
[PubMed - indexed for MEDLINE]
4.

[A comparative evaluation of immunomodulating drugs in the treatment of remitting multiple sclerosis].

Zvartau ME, Kaon K, Lisak RF, Kan OA, Skoromets AA.

Zh Nevrol Psikhiatr Im S S Korsakova. 2004;104(7):66-71. Review. Russian. No abstract available.

PMID:
15347038
[PubMed - indexed for MEDLINE]
5.

Interferons in relapsing remitting multiple sclerosis.

Kolar OJ, Bauerle JA, Lee H.

Lancet. 2003 May 24;361(9371):1825. No abstract available.

PMID:
12781563
[PubMed - indexed for MEDLINE]
6.

Clinical characteristics of responders to interferon therapy for relapsing MS.

Villoslada P, Oksenberg JR, Rio J, Montalban X.

Neurology. 2004 May 11;62(9):1653; author reply 1653. No abstract available.

PMID:
15136712
[PubMed - indexed for MEDLINE]
7.

Evaluation of response of multiple sclerosis (MS) relapse to oral high-dose methylprednisolone: usefulness of MS functional composite and Expanded Disability Status Scale.

Pascual AM, Boscá I, Coret F, Escutia M, Bernat A, Casanova B.

Eur J Neurol. 2008 Mar;15(3):284-8. doi: 10.1111/j.1468-1331.2008.02061.x.

PMID:
18290849
[PubMed - indexed for MEDLINE]
8.

Drug Insight: interferon treatment in multiple sclerosis.

Ann Marrie R, Rudick RA.

Nat Clin Pract Neurol. 2006 Jan;2(1):34-44. Review.

PMID:
16932519
[PubMed - indexed for MEDLINE]
9.

Predicting responders to therapies for multiple sclerosis.

Río J, Comabella M, Montalban X.

Nat Rev Neurol. 2009 Oct;5(10):553-60. doi: 10.1038/nrneurol.2009.139. Review.

PMID:
19794514
[PubMed - indexed for MEDLINE]
10.

Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.

Carmona O, Casado V, Moral E, Alonso-Magdalena L, Martínez-Yélamos A, Martínez-Yélamos S, Martín-Ozaeta G, Arbizu T.

Eur Neurol. 2008;60(6):279-84. doi: 10.1159/000157881. Epub 2008 Sep 27.

PMID:
18824855
[PubMed - indexed for MEDLINE]
11.

Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.

Earnshaw SR, Graham J, Oleen-Burkey M, Castelli-Haley J, Johnson K.

Appl Health Econ Health Policy. 2009;7(2):91-108. doi: 10.2165/11314900-000000000-00000.

PMID:
19731967
[PubMed - indexed for MEDLINE]
12.

Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study.

Oturai AB, Koch-Henriksen N, Petersen T, Jensen PE, Sellebjerg F, Sorensen PS.

Eur J Neurol. 2009 Mar;16(3):420-3. doi: 10.1111/j.1468-1331.2008.02517.x.

PMID:
19364368
[PubMed - indexed for MEDLINE]
13.

Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.

[No authors listed]

Expert Rev Pharmacoecon Outcomes Res. 2009 Jun;9(3):198. doi: 10.1586/erp.09.25. No abstract available.

PMID:
19527090
[PubMed - indexed for MEDLINE]
14.

[Multiple sclerosis: can therapy delay ongoing disability?].

Havla J, Pellkofer HL, Hohlfeld R, Kümpfel T.

MMW Fortschr Med. 2011 Apr 7;153(14):63-6. Review. German. No abstract available.

PMID:
21966873
[PubMed - indexed for MEDLINE]
15.

[Experience in copaxon treatment in Russia].

Zavalishin IA, Peresedova AV, Stoĭda NI, Adarcheva LS, Zakharova MN, Niiazbekova AS, Askarova LSh, Rebrova OIu.

Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(8):29-31. Russian. No abstract available.

PMID:
16180496
[PubMed - indexed for MEDLINE]
16.

Factors associated with the risk of secondary progression in multiple sclerosis.

Koch M, Uyttenboogaart M, van Harten A, De Keyser J.

Mult Scler. 2008 Jul;14(6):799-803. doi: 10.1177/1352458508089361. Epub 2008 Jun 23.

PMID:
18573840
[PubMed - indexed for MEDLINE]
17.

Early interferon beta treatment in multiple sclerosis: nursing care implications of the BENEFIT study.

Webb UH.

J Neurosci Nurs. 2008 Dec;40(6):356-61. Review.

PMID:
19170303
[PubMed - indexed for MEDLINE]
18.

Oral cladribine and fingolimod for relapsing multiple sclerosis.

Li H, Zhang X.

N Engl J Med. 2010 May 6;362(18):1738-9; author reply 1739-40. No abstract available. Erratum in: N Engl J Med. 2010 Jul 15;363(3):298.

PMID:
20449878
[PubMed - indexed for MEDLINE]
19.

How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?

Sorensen PS.

Eur J Neurol. 2009 Mar;16(3):287-8. doi: 10.1111/j.1468-1331.2008.02518.x. No abstract available.

PMID:
19364360
[PubMed - indexed for MEDLINE]
20.

Interferons in relapsing remitting MS: a systematic review comments on a meta-analysis.

Clanet M, Cucheratt M.

Int MS J. 2003 Dec;10(4):134-5.

PMID:
14977491
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk